EGEIRO PHARMA
Voor EGEIRO PHARMA is een faillissementsprocedure geopend volgens publicaties in het Belgisch Staatsblad. De jaarrekening over 2023 toont een eigen vermogen van €6,05M en een nettoresultaat van €-1,57M.
| Eigen vermogen | €6,05M |
| Netto resultaat | €-1,57M |
| Werknemers (VTE) | 7,5 |
| Beter dan sector | 85% |
Kwetsbaar profiel, let vooral op gezondheid.
Alle 5 assen zijn berekend uit gegevens die Checked heeft ingelezen.
Faillissement geopend
Er loopt al een faillissementsprocedure, een kans-score is dan niet meer zinvol. Bekijk de insolventietijdlijn voor de stand van de procedure.
De volledige opbouw van de score, de scoregeschiedenis per boekjaar en de indicatieve kredietlimiet ontgrendel je met Plus.
Bekijk plannen →| Kengetal | Dit bedrijf | Sectormediaan | Positie in de sector |
|---|---|---|---|
| Solvabiliteit | 80,3% | 25,2% | |
| Nettoresultaat | €-1,57M | €-3k | |
| Eigen vermogen | €6,05M | €35k | |
| Personeelskosten | €770k | €548k | |
| Werknemers (VTE) | 7,5 | 14,3 |
| Boekjaar | 2023 |
|---|---|
| Neerlegging | volledig |
| Omzet | €118k |
| EBITDA | €-1,11M |
| Nettoresultaat | €-1,57M |
| Cashflow | €-507k |
| Personeelskosten | €770k |
| Belastingen op het resultaat | €-46k |
| Dividenden | - |
| Totaal activa | €7,53M |
| Eigen vermogen | €6,05M |
| Schulden | €1,48M |
| waarvan ≤ 1 jaar | €477k |
| waarvan > 1 jaar | €1,00M |
| Werkkapitaal | €1,17M |
| Werknemers (VTE) | 7,5 |
| 2023 | |
|---|---|
| Current ratio | 3,45 |
| Quick ratio | 3,19 |
| Werkkapitaalratio | 15,5% |
| Solvabiliteit | 80,3% |
| Debt / equity | 0,25 |
| Langetermijnschuldgraad | 0,17 |
| Interest coverage | -40,28 |
| Bruto rentabiliteit | 36,7% |
| Netto rentabiliteit | -1332,9% |
| ROA | -20,8% |
| ROE | -26,0% |
| EBITDA-marge | -942,9% |
| Klantenkrediet (DSO) | 56d |
| Leverancierskrediet (DPO) | 644d |
| Voorraadrotatie | 0,60 |
| Voorraaddagen (DSI) | 604d |
| Post | Code | 2023 |
|---|---|---|
| Balans, Activa | ||
| TOTAAL ACTIVA | 20/58 | €7,53M |
| Vaste activa | 21/28 | €5,44M |
| Oprichtingskosten | 20 | €452k |
| Immateriële vaste activa | 21 | €5,21M |
| Materiële vaste activa | 22/27 | €22k |
| Financiële vaste activa | 28 | €201k |
| Vlottende activa | 29/58 | €1,65M |
| Voorraden en bestellingen in uitvoering | 3 | €123k |
| Vorderingen op ten hoogste één jaar | 40/41 | €334k |
| Liquide middelen | 54/58 | €1,15M |
| Balans, Passiva | ||
| TOTAAL PASSIVA | 10/49 | €7,53M |
| Eigen vermogen | 10/15 | €6,05M |
| Inbreng / kapitaal | 10/11 | €10,17M |
| Overgedragen winst (verlies) | 14 | €-5,84M |
| Schulden | 17/49 | €1,48M |
| Schulden op meer dan één jaar | 17 | €1,00M |
| Schulden op ten hoogste één jaar | 42/48 | €477k |
| Handelsschulden op ten hoogste één jaar | 44 | €132k |
| Resultatenrekening | ||
| Omzet | 70 | €118k |
| Bedrijfsresultaat | 9901 | €-2,18M |
| Financiële opbrengsten | 75 | €594k |
| Financiële kosten | 65 | €35k |
| Resultaat vóór belasting | 9903 | €-1,62M |
| Belastingen op het resultaat | 67/77 | €-46k |
| Resultaat van het boekjaar | 9904 | €-1,57M |
| Te bestemmen resultaat | 9905 | €-1,57M |
-
Catherine Suzanne Madeleine BurBestuurderStaatsblad-akte 24442799 (12-11-2024)Actief12-11-2024 → heden
-
Emmanuel Gilbert Hyunh-Kim-BangBestuurderStaatsblad-akte 24442799 (12-11-2024)Actief12-11-2024 → heden
-
Gaëtan TerrasseDagelijks bestuurStaatsblad-akte 24175571 (13-12-2024)Actief12-11-2024 → heden
2 gebeurtenissen
- 13-12-2024 Benoemd· Dagelijks bestuur
- 12-11-2024 Benoemd· Bestuurder
-
FATAKI BVRechtspersoonBestuurderStaatsblad-akte 24108740 (18-07-2024)Actief18-07-2024 → heden
-
Mélanie AdoranteRepresentative of the commissionerStaatsblad-akte 23079634 (20-06-2023)Actief20-06-2023 → heden
-
NESYA GORIS LIFESCIENCES CONSULTING BVRechtspersoonBestuurderStaatsblad-akte 22074510 (23-06-2022)Actief22-02-2022 → heden
2 gebeurtenissen
- 23-06-2022 Benoemd· Bestuurder
- 22-02-2022 Benoemd· Bestuurder
-
Vel-Vet AH ConsultingObservateurStaatsblad-akte 22024019 (22-02-2022)Actief22-02-2022 → heden
-
Innovation Fund SARechtspersoonBestuurderStaatsblad-akte 21069923 (14-06-2021)Actief14-06-2021 → heden
Historisch, niet recent bevestigd (3)
-
Christian JourquinAdministratorStaatsblad-akte 18091382 (13-06-2018)Niet recent bevestigdlaatst bevestigd in akte van 2018
-
Mohamed Lotfi Yelles ChaoucheAdministratorStaatsblad-akte 18091382 (13-06-2018)Niet recent bevestigdlaatst bevestigd in akte van 2018
-
Pierre DetrixheAdministratorStaatsblad-akte 18091382 (13-06-2018)Niet recent bevestigdlaatst bevestigd in akte van 2018
Voormalige bestuurders (12)
-
Catherine BURDagelijks bestuurStaatsblad-akte 24165401 (22-11-2024)Voormalig22-11-2024 → 13-12-2024
2 gebeurtenissen
- 13-12-2024 Ontslagen· Dagelijks bestuur
- 22-11-2024 Benoemd· Dagelijks bestuur
-
ENRICO BASTIANELLIBestuurderStaatsblad-akte 24442799 (12-11-2024)Voormalig13-06-2018 → 13-12-2024
4 gebeurtenissen
- 13-12-2024 Ontslagen· Bestuurder
- 12-11-2024 Ontslagen· Bestuurder
- 12-11-2024 Benoemd· Bestuurder
- 13-06-2018 Benoemd· Administrator
-
ENRICO BASTIANELLI SRLRechtspersoonBestuurderStaatsblad-akte 24108740 (18-07-2024)Voormalig18-07-2024 → 22-11-2024
2 gebeurtenissen
- 22-11-2024 Ontslagen· Dagelijks bestuur
- 18-07-2024 Benoemd· Bestuurder
-
FatakiBestuurderStaatsblad-akte 24442799 (12-11-2024)Voormalig- → 12-11-2024
-
Nesya Goris LifeSciences ConsultingBestuurderStaatsblad-akte 24442799 (12-11-2024)Voormalig- → 12-11-2024
-
Simon WheelerBestuurderStaatsblad-akte 22074510 (23-06-2022)Voormalig22-02-2022 → 12-11-2024
4 gebeurtenissen
- 12-11-2024 Ontslagen· Bestuurder
- 23-06-2022 Benoemd· Bestuurder
- 22-02-2022 Benoemd· Bestuurder
- 22-02-2022 Benoemd· Président du conseil
-
CAPITAL & CROISSANCE SCRLRechtspersoonBestuurderStaatsblad-akte 23149336 (23-11-2023)Voormalig- → 23-11-2023
-
Julie WinandAdministratorStaatsblad-akte 18091382 (13-06-2018)Voormalig13-06-2018 → 23-11-2023
2 gebeurtenissen
- 23-11-2023 Ontslagen· Bestuurder
- 13-06-2018 Benoemd· Administrator
-
Patrick MortouxRepresentative of the commissionerStaatsblad-akte 23079634 (20-06-2023)Voormalig- → 20-06-2023
-
VEL-VET AH CONSULTING SASBestuurderStaatsblad-akte 22074510 (23-06-2022)Voormalig23-06-2022 → 05-01-2023
2 gebeurtenissen
- 05-01-2023 Ontslagen· Bestuurder
- 23-06-2022 Benoemd· Bestuurder
-
EEBIC Ventures SARechtspersoonBestuurderStaatsblad-akte 21069923 (14-06-2021)Voormalig14-06-2021 → 22-02-2022
3 gebeurtenissen
- 22-02-2022 Ontslagen· Bestuurder
- 22-02-2022 Ontslagen· Président du conseil
- 14-06-2021 Benoemd· Bestuurder
-
André OstachkovBestuurderStaatsblad-akte 21125397 (21-10-2021)Voormalig- → 21-10-2021
| Commissaris / bedrijfsrevisor | IBR/IRE-nummer | Periode |
|---|---|---|
| Mélanie AdoranteActief Commissaire |
- | 10-11-2022 → heden |
| SC PwC Réviseurs d'EntreprisesActief Commissaire |
- | 23-06-2022 → heden |
| Patrick Mortroux Commissaire aux comptes |
- | 13-08-2020 → 10-11-2022 |
| Rol | Naam | Periode | Bron |
|---|---|---|---|
| Curator | PIERRE-EMMANUEL CORNIL RUE DE GOZEE, 137,
6110 MONTIGNY-LE-TILLEUL |
17-03-2025 → heden | Belgisch Staatsblad |
| NACE primair | 20130 |
| Rechtsvorm | NV(014) |
| Oprichtingsdatum | 22-11-2017 |
| Status | Actief |
| Postcode | 6041 |
| Eerste BS-signaal | 21-03-2025 |
| Laatste BS-signaal | 21-03-2025 |
Percelen gekoppeld aan dit bedrijf via zijn adressen in de KBO (zetel, vestigingen, bijkantoren), gekruist met het kadastraal percelenplan. Dit toont waar het bedrijf actief is, geen eigendomsregister.
| Perceel (capakey) | Regio | Oppervlakte | Gebouwen | Hoogte / verd. |
|---|---|---|---|---|
| 52028B0315/18E000 | Wallonië | 2.954 m² | 1 · 670 m² | 10,0 m · 2 verd. |
| 21307F0170/00S002 | Brussel | 2.186 m² | 1 · 2.167 m² | 17,9 m · 2 verd. |
Eén tijdlijn van alles wat er met dit bedrijf is gebeurd, publicaties, insolventie- en levensloopgebeurtenissen, administratieve wijzigingen en neergelegde jaarrekeningen.
20-12-2024 Statutenwijziging
Technische details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "EGEIRO PHARMA"
},
"legal_form_change": {
"new": "Soci\u00E9t\u00E9 anonyme",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}17-12-2024 Kapitaalverhoging van €33.138,20 tot €12.254.462,48
- €12.221.324,28 → €12.254.462,48
- Inbreng in geld · Apport en numéraire
Technische details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 12254462.48,
"delta_eur": 33138.20000000112,
"before_eur": 12221324.28,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "EGEIRO PHARMA"
}
}13-12-2024 1 bestuurder benoemd, 2 ontslagnemend
- Gaëtan Terrasse, Dagelijks bestuur
- Enrico Bastianelli, Bestuurder
- Catherine Bur, Dagelijks bestuur
Technische details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Enrico Bastianelli",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re",
"person": {
"rrn": null,
"name": "Catherine Bur",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re",
"person": {
"rrn": null,
"name": "Ga\u00EBtan Terrasse",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "EGEIRO PHARMA"
}
}22-11-2024 1 bestuurder benoemd, 1 ontslagnemend
- Catherine BUR, Dagelijks bestuur
- ENRICO BASTIANELLI SRL, Dagelijks bestuur
Technische details
{
"events": [
{
"kind": "director_out",
"role": "d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re",
"person": {
"rrn": null,
"name": "ENRICO BASTIANELLI SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re",
"person": {
"rrn": null,
"name": "Catherine BUR",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "EGEIRO PHARMA"
}
}12-11-2024 Kapitaalverhoging van €11.864.406,78 tot €12.221.324,28
- €356.917,50 → €12.221.324,28
- Inbreng in natura · Apport en nature
Technische details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 12221324.28,
"delta_eur": 11864406.78,
"before_eur": 356917.5,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
}
}18-09-2024 Kapitaalverhoging van €15.495,80 tot €356.917,50
- €341.421,70 → €356.917,50
- Inbreng in geld · Apport en numéraire
Technische details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 356917.5,
"delta_eur": 15495.799999999988,
"before_eur": 341421.7,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
}
}06-09-2024 Kapitaalverhoging van €19.008,10 tot €341.421,70
- €322.413,60 → €341.421,70
- Inbreng in geld · Apport en numéraire
Technische details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 341421.7,
"delta_eur": 19008.100000000035,
"before_eur": 322413.6,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
}
}18-07-2024 2 bestuurders benoemd
- FATAKI BV, Bestuurder
- ENRICO BASTIANELLI SRL, Bestuurder
Technische details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "FATAKI BV",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "ENRICO BASTIANELLI SRL",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVET"
}
}23-11-2023 2 ontslagnemend
- Julie WINAND, Bestuurder
- CAPITAL & CROISSANCE SCRL, Bestuurder
Technische details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Julie WINAND",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "CAPITAL \u0026 CROISSANCE SCRL",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVET"
}
}20-06-2023 1 bestuurder benoemd, 1 ontslagnemend
- Mélanie Adorante, Representative of the commissioner
- Patrick Mortoux, Representative of the commissioner
Technische details
{
"events": [
{
"kind": "director_in",
"role": "representative of the commissioner",
"person": {
"rrn": null,
"name": "M\u00E9lanie Adorante",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "representative of the commissioner",
"person": {
"rrn": null,
"name": "Patrick Mortoux",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVET"
}
}05-01-2023 VEL-VET AH CONSULTING SAS neemt ontslag als bestuurder
- VEL-VET AH CONSULTING SAS, Bestuurder
Technische details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "VEL-VET AH CONSULTING SAS",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVET"
}
}10-11-2022 1 bestuurder benoemd, 1 ontslagnemend
- Mélanie Adorante, Commissaire
- Patrick Mortroux, Commissaire
Technische details
{
"events": [
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "M\u00E9lanie Adorante",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "commissaire",
"person": {
"rrn": null,
"name": "Patrick Mortroux",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
}
}23-06-2022 4 bestuurders benoemd
- NESYA GORIS LIFESCIENCES CONSULTING BV, Bestuurder
- Simon Wheeler, Bestuurder
- VEL-VET AH CONSULTING SAS, Bestuurder
- SC PwC Réviseurs d'Entreprises, Commissaire
Technische details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "NESYA GORIS LIFESCIENCES CONSULTING BV",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Simon Wheeler",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "VEL-VET AH CONSULTING SAS",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "SC PwC R\u00E9viseurs d\u0027Entreprises",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVET"
}
}22-02-2022 4 bestuurders benoemd, 2 ontslagnemend
- Nesya Goris LifeSciences Consulting BV, Bestuurder
- Simon Wheeler, Bestuurder
- Simon Wheeler, Président du conseil
- Vel-Vet AH Consulting, Observateur
- EEBIC Ventures SA, Bestuurder
- EEBIC Ventures SA, Président du conseil
Technische details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Nesya Goris LifeSciences Consulting BV",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "EEBIC Ventures SA",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Pr\u00E9sident du Conseil",
"person": {
"rrn": null,
"name": "EEBIC Ventures SA",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Simon Wheeler",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Pr\u00E9sident du Conseil",
"person": {
"rrn": null,
"name": "Simon Wheeler",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "observateur",
"person": {
"rrn": null,
"name": "Vel-Vet AH Consulting",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "Innovation Fund SA"
}
}21-10-2021 André Ostachkov neemt ontslag als bestuurder
- André Ostachkov, Bestuurder
Technische details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Andr\u00E9 Ostachkov",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVET"
}
}30-09-2021 Zetelverplaatsing van Jumet naar Charleroi
- Rue d'Edimbourg 11, boite B, 6040 Jumet → 6041 Charleroi, Avenue Jean Mermoz 32/1, Bâtiment BIOTECH 3
Technische details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "siege_social",
"new_address": {
"raw": "6041 Charleroi, Avenue Jean Mermoz 32/1, B\u00E2timent BIOTECH 3",
"city": "Charleroi",
"region": "waals_gewest",
"street": "Avenue Jean Mermoz",
"country": "BE",
"postcode": "6041",
"box_number": null,
"street_number": "32/1",
"locality_suffix": null
},
"old_address": {
"raw": "Rue d\u0027Edimbourg 11, boite B, 6040 Jumet",
"city": "Jumet",
"region": "waals_gewest",
"street": "Rue d\u0027Edimbourg",
"country": "BE",
"postcode": "6040",
"box_number": "B",
"street_number": "11",
"locality_suffix": null
},
"effective_date": "2021-09-15",
"evidence_quote": "Les Administrateurs d\u00E9cident de transf\u00E9rer le si\u00E8ge de la Soci\u00E9t\u00E9 \u00E0 6041 Charleroi, Avenue Jean Mermoz 32/1, B\u00E2timent BIOTECH 3, avec effet au 15 septembre 2021.",
"region_changed": false,
"is_statute_change": false,
"nationality_change": false,
"old_address_source": "act_body",
"statute_clause_text": null,
"statute_article_number": null,
"effective_date_qualifier": "retroactive",
"statutaire_vs_werkelijke": "statutaire",
"linguistic_region_changed": false,
"court_jurisdiction_changed": false,
"effective_date_is_approximate": false
}
],
"notary": {
"name": "Bjorn Delmoiti\u00E9",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2021-09-30",
"filing_date": "2021-09-13",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "raad_van_bestuur",
"date": "2021-09-13",
"unanimous": true
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVET",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": "Harvest Avocats",
"person_name": "Adrien Lanotte",
"org_rep_person_name": "Bjorn Delmoiti\u00E9",
"person_role_at_subject": "avocat"
},
"co_filed_documents": [
"Extrait des r\u00E9solutions \u00E9crites et unanimes des administrateurs",
"Procuration aux avocats"
]
}12-07-2021 Statutenwijziging
Technische details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": true
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
},
"legal_form_change": {
"new": "soci\u00E9t\u00E9 anonyme",
"old": "soci\u00E9t\u00E9 anonyme",
"changed": false
}
}14-06-2021 2 bestuurders benoemd
- EEBIC Ventures SA, Bestuurder
- Innovation Fund SA, Bestuurder
Technische details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "EEBIC Ventures SA",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Innovation Fund SA",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
}
}13-08-2020 Patrick Mortroux benoemd tot commissaire aux comptes
- Patrick Mortroux, Commissaire aux comptes
Technische details
{
"events": [
{
"kind": "director_in",
"role": "commissaire aux comptes",
"person": {
"rrn": null,
"name": "Patrick Mortroux",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "THERAVEET"
}
}22-06-2020 Kapitaalverhoging van €114.025 tot €248.930
- €134.905 → €248.930
- Inbreng in geld · Apport en numéraire
Technische details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 248930,
"delta_eur": 114025,
"before_eur": 134905,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
}
}06-11-2018 Statutenwijziging
Technische details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "TheraVet",
"old": "BoneVet",
"changed": true
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "TheraVet"
},
"legal_form_change": {
"new": "Soci\u00E9t\u00E9 anonyme",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}13-06-2018 5 bestuurders benoemd
- Enrico Bastianelli, Administrator
- Julie Winand, Administrator
- Mohamed Lotfi Yelles Chaouche, Administrator
- Christian Jourquin, Administrator
- Pierre Detrixhe, Administrator
Technische details
{
"events": [
{
"kind": "director_in",
"role": "administrator",
"person": {
"rrn": null,
"name": "Enrico Bastianelli",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrator",
"person": {
"rrn": null,
"name": "Julie Winand",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrator",
"person": {
"rrn": null,
"name": "Mohamed Lotfi Yelles Chaouche",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrator",
"person": {
"rrn": null,
"name": "Christian Jourquin",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrator",
"person": {
"rrn": null,
"name": "Pierre Detrixhe",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "BONEVET"
}
}15-01-2018 Kapitaalverhoging van €44.967 tot €107.467
- €62.500 → €107.467
- Inbreng in geld · Apport en numéraire
Technische details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 107467,
"delta_eur": 44967,
"before_eur": 62500,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0684.906.013",
"name_full": "BoneVet"
}
}24-11-2017 Oprichting van een SA
Technische details
{
"notary": {
"name": "Bertrand NERINCX",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2017-11-24",
"filing_date": "2017-11-22",
"act_kind_objet": "Objet de l\u0027acte:",
"is_private_deed": false
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2017-11-21",
"unanimous": true
},
"founders": [
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1969-01-18",
"name": "Enrico BASTIANELLI",
"niss": null,
"address": "1640 Rhode-Saint-Gen\u00E8se, Avenue de la Lib\u00E9ration 41",
"nationality": "Belgique",
"place_of_birth": "Ixelles, Belgique"
},
"share_class": null,
"partner_role": null,
"contribution_type": "geld",
"amount_paid_in_eur": 56250.0,
"is_subscriber_only": false,
"n_shares_subscribed": 56250,
"amount_subscribed_eur": 56250.0,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": "0547.864.809",
"name": "GLOB-CO",
"address": "6041 Charleroi (Gosselies), Rue Adrienne Bolland 8",
"country": "BE",
"legal_form": "BV",
"foreign_register_name": null,
"foreign_register_number": null
},
"kind": "rechtspersoon",
"person": null,
"share_class": null,
"partner_role": null,
"contribution_type": "geld",
"amount_paid_in_eur": 6250.0,
"is_subscriber_only": false,
"n_shares_subscribed": 6250,
"amount_subscribed_eur": 6250.0,
"is_anonymous_silent_partner": false
}
],
"voorwerp": {
"full_text": "La soci\u00E9t\u00E9 a pour objet, tant en Belgique qu\u2019\u00E0 l\u2019\u00E9tranger, pour compte propre ou pour compte de tiers, toutes activit\u00E9s se rapportant directement ou indirectement \u00E0 la recherche, \u00E0 la conception, \u00E0 la validation, au d\u00E9veloppement, \u00E0 la production, au conditionnement, et \u00E0 la distribution ou commercialisation de compos\u00E9s chimiques ou radiochimiques, de m\u00E9dicaments, de produits biotechnologiques, de dispositifs m\u00E9dicaux, de formulations gal\u00E9niques originales de m\u00E9dicaments, ainsi que de produits sp\u00E9cifiques de recherche m\u00E9dicale, pharmaceutique, cosm\u00E9tique et biotechnologique pour la sant\u00E9 v\u00E9t\u00E9rinaire et pour la sant\u00E9 humaine ou toute mati\u00E8re dans les domaines pr\u00E9cit\u00E9s. La soci\u00E9t\u00E9 peut rendre des services de soutien et conseil dans les domaines pr\u00E9cit\u00E9s \u00E0 des tiers et en particulier, \u00E0 des soci\u00E9t\u00E9s dans lesquelles elle d\u00E9tient une participation directe ou indirecte. Elle aura aussi pour objet tant en Belgique qu\u2019\u00E0 l\u2019\u00E9tranger la d\u00E9tention et la gestion, directement ou indirectement, de participations dans d\u2019autres soci\u00E9t\u00E9s ayant un objet directement ou indirectement li\u00E9 \u00E0 la recherche, au d\u00E9veloppement, \u00E0 des activit\u00E9s industrielles ou commerciales se focalisant principalement mais non exclusivement sur l\u2019industrie pharmaceutique, biotechnologique ou des dispositifs m\u00E9dicaux. Elle aura plus g\u00E9n\u00E9ralement pour objet toutes les op\u00E9rations commerciales, financi\u00E8res, industrielles, mobili\u00E8res ou immobili\u00E8res se rattachant directement ou indirectement \u00E0 son objet social ou de nature \u00E0 en favoriser le d\u00E9veloppement, en ce compris toutes op\u00E9rations en rapport avec l\u2019exploitation de droits intellectuels quelconques et autres marques, brevets, inventions, droit d\u2019usage, licences. La soci\u00E9t\u00E9 peut r\u00E9aliser son objet, directement ou indirectement, en nom propre ou pour compte de tiers, seule ou en association en effectuant toutes op\u00E9rations de nature \u00E0 favoriser le dit objet ou celui des soci\u00E9t\u00E9s, associations, \u00E9tablissements dans lesquels elle d\u00E9tient une participation. La soci\u00E9t\u00E9 peut \u00E9galement donner caution ou octroyer des s\u00FBret\u00E9s tant pour ses propres engagements que pour les engagements des tiers, entre autres, en donnant ses biens en hypoth\u00E8que ou en gage, y compris en gageant son fonds de commerce. La soci\u00E9t\u00E9 pourra exercer tous mandats relatifs \u00E0 l\u0027administration, \u00E0 la gestion, \u00E0 la direction, au contr\u00F4le et \u00E0 la liquidation de toutes soci\u00E9t\u00E9s ou entreprises. La soci\u00E9t\u00E9 pourra \u00E9galement s\u0027int\u00E9resser de quelque mani\u00E8re que ce soit et notamment par voie de cr\u00E9ation de soci\u00E9t\u00E9s, d\u2019apports et de fusions, de souscriptions ou d\u2019achats de titres, de droits sociaux et de participations dans toutes entreprises dont l\u0027activit\u00E9 ou l\u2019objet serait similaire ou connexe en tout ou en partie \u00E0 celui ci-dessus d\u00E9crit et qui serait susceptible de concourir au d\u00E9veloppement de ses activit\u00E9s, en Belgique comme \u00E0 l\u2019\u00E9tranger.",
"is_lucrative": true,
"short_summary": "Recherche, d\u00E9veloppement, production, distribution et commercialisation de compos\u00E9s chimiques, radiochimiques, m\u00E9dicaments, produits biotechnologiques, dispositifs m\u00E9dicaux et formulations gal\u00E9niques pour la sant\u00E9 v\u00E9t\u00E9rinaire et humaine."
},
"governance": {
"organ_kind": "raad_van_bestuur",
"n_directors_max": null,
"n_directors_min": 2,
"representation_clause": "deux administrateurs agissant conjointement",
"co_signature_threshold_eur": null
},
"fiscal_year": {
"end_mm_dd": "12-31",
"start_mm_dd": "01-01",
"first_exercise_end_date": "2018-12-31",
"is_prolonged_first_exercise": false
},
"agm_schedule": {
"time": "17:00",
"month": 6,
"rule_text": "premier jeudi de juin \u00E0 dix-sept heures"
},
"founding_event": {
"n_shares_total": 62500,
"n_share_classes": 1,
"bank_attestation": {
"date": "2017-11-21",
"bank_name": "ING",
"amount_eur": 62500.0,
"iban_masked": "BE43 3632 6778 4001"
},
"amount_paid_in_eur": 62500.0,
"incorporation_date": "2017-11-21",
"amount_subscribed_eur": 62500.0,
"art_5_8_no_payment_due": false,
"pre_incorporation_activity_from_date": "2017-10-01"
},
"subject_company": {
"kbo": "0684.906.013",
"email": null,
"region": "waals_gewest",
"website": null,
"name_full": "BoneVet",
"legal_form": "SA",
"name_abbreviated": "BoneVet",
"zetel_address_raw": "6041 Charleroi, Rue Auguste Piccard 48",
"equity_account_type": "available",
"_kbo_extracted_mismatch": "0547.864.809"
},
"initial_directors": [
{
"kind": "rechtspersoon",
"person": null,
"via_org": {
"kbo": "0883.830.544",
"name": "ENRICO BASTIANELLI",
"legal_form": "BV"
},
"role_sub": "administrateur",
"mandate_until": {
"kind": "until_agm_year",
"value": 2023
},
"rep_person_name": "Enrico BASTIANELLI",
"additional_roles": [
"pr\u00E9sident"
],
"bestuursverbod_checked": false,
"bestuursverbod_check_date": null,
"rep_prior_publication_ref": {
"date": "2017-11-21",
"numac_or_number": "0684906013"
}
},
{
"kind": "natural_person",
"person": {
"name": "Julie Marie-Jos\u00E9 WINAND",
"address": "1400 Nivelles, Avenue de la Libert\u00E9 29, 3F"
},
"via_org": null,
"role_sub": "administrateur",
"mandate_until": {
"kind": "until_agm_year",
"value": 2023
},
"rep_person_name": null,
"additional_roles": [],
"bestuursverbod_checked": false,
"bestuursverbod_check_date": null,
"rep_prior_publication_ref": null
}
],
"co_filed_documents": [
"expedition",
"statuten",
"volmacht"
],
"post_incorporation_mandates": [
{
"kind": "volmacht_kbo",
"holder_org_kbo": "0479.092.007",
"holder_org_name": "KREANOVE",
"with_substitution": true,
"holder_person_name": null
}
]
}Genereer een gestructureerde, feitelijke nota op basis van alle signalen in dit dossier: risico, financiële gezondheid, eigendomsstructuur, mandaten en sectorvergelijking.
| Officiële naamFR | EGEIRO PHARMA |